Stablecoin Development Corp 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS   None.   ITEM 3. DEFAULTS UPON SENIOR SECURITIES   None.   ITEM 4. MINE SAFETY DISCLOSURE   Not Applicable.   ITEM 5.   OTHER INFORMATION   On August 10, 2021, the Company terminated the Microprofit Agreement, dated April 16, 2020, with Microprofit and the Distribution Agreement, dated April 16, 2020, with Chongqing Pioneer, as amended by the First Amendment, dated June 29, 2020, the terms of which were previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on April 20, 2020 and the Company’s Quarter Report on Form 10-Q filed with the SEC on August 6, 2020.   Pursuant to the Microprofit Agreement and the Distribution Agreement, Microprofit granted the Company exclusive rights to distribute the Test Kits in the United States through December 31, 2021, subject to various assumptions including the approval by the FDA, with Chongqing Pioneer to act as an intermediary between Microprofit and the Company in the distribution of the Test Kits if approved by the FDA. As previously disclosed, on June 7, 2021, the Company was notified by the FDA that it declined to review the Company’s Emergency Use Authorization request for the Test Kits. As such, the Test Kits are not authorized to be distributed or used as proposed in the United States, and the Microprofit Agreement and Distribution Agreement were terminated by the parties mutual agreement for administrative and accounting purposes.   -42- Table of Contents   ITEM 6.   EXHIBITS   The following exhibits are filed with or incorporated by reference into this report.   EXHIBIT INDEX       Incorporation by Reference Filed Herewith Exhibit Number Exhibit Description Form File Number Exhibit/ Form 8-K Item Reference Filing Date   3.1 Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc. 10-K 001-33678 3.1 3/21/2018   3.2 Amendment to the Amended and Restated Certificate of Incorporation, dated June 4, 2018 8-K 001-33678 3.1 6/04/2018   3.3 Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 27, 2020 8-K 001-33678 3.1 5/28/2020   3.4 Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 24, 2021 8-K 001-33678 3.1 5/24/2021   3.5 Bylaws 8-K 001-33678 3.2 6/29/2010   4.1 Form of Warrant pursuant to the Services Agreement with TLF Bio Innovation Lab, LLC, dated May 13, 2020 8-K 001-33678 4.1 5/18/2020   4.2 Form of July 2020 Warrant 8-K 001-33678 4.1 7/21/2020   10.1 At the Market Offering Agreement, dated May 14, 2021, between NovaBay Pharmaceuticals, Inc. and Ladenburg Thalmann & Co. Inc. 8-K 001-33678 1.1 5/14/2021   31.1 Certification of the Principal Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)         X 31.2 Certification of the Principal Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)         X 32.1 Certification by the Chief Executive Officer   of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18   U.S.C. 1350)         X 32.2 Certification by the Chief Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18   U.S.C. 1350)         X 101.INS Inline XBRL Instance Document         X 101.SCH Inline XBRL Taxonomy Extension Schema Document          X 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document         X 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase         X 101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document         X 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document         X 104 Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)             -43- Table of Contents     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.     Date: August 12, 2021 NOVABAY PHARMACEUTICALS, INC.       /s/ Justin Hall    Justin Hall    Chief Executive Officer (principal executive officer)     Date: August 12, 2021 /s/ Andrew Jones   Andrew Jones   Chief Financial Officer (principal financial officer)